Haleon believes it is not liable for any claims that may arise from U.S. litigation over allegations the Zantac heartburn drug contains a probable carcinogen.

He quickly moves on to a Zantac wine glass from 1983, when the heartburn drug was approved for sale in the US, and then a white and blue Zantac Swiss army knife. A globe, then a t-shirt, next a ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...

GSK agreed to settle a U.S. lawsuit alleging its discontinued heartburn drug Zantac caused cancer, the British drugmaker said on Friday, preventing the first such case from going to trial next month.

The blue-chip FTSE 100 moved 0.5pc higher, ... drug giant has agreed to pay up to $2.2bn to settle tens of thousands of US lawsuits claiming its heartburn drug Zantac caused cancer.

Shares in GSK rose more than 2% to a 10-month high of 1,559 pence on Wednesday, briefly making it the best performer on London's blue-chip FTSE 100 , opens new tab. There were last up 0.65%.

The Food and Drug Administration asked in 2020 that all Zantac products, which relied on a heartburn drug developed by GSK, be taken off the market. The current Zantac 360 uses a different active ...

March 24 (Reuters) - A California judge on Thursday denied GSK Plc's , opens new tab bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial ...

T op of the morning to you, and a fine one it is. There is nothing like being greeted with clear blue skies and cool breezes upon waking up today on the Pharmalot campus. Birds are chirping ...

Zantac (aka ranitidine) was one of pharma’s first blockbusters, meaning sales of more than $1bn a year. ... It shows GSK, the dark blue line, being hit hardest and taking longest to recover.

A California judge on Thursday denied GSK Plc's bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial, a setback for the British drugmaker ...